Para a página inicial
4.6/5
TrustPilot

Compare os principais médicos e preços de RM-PET em Turquia. Encontre o seu melhor par aqui.

Receba orçamentos de 3 principais especialistas em RM-PET em Turquia

Vamos selecionar os melhores médicos com base nas suas necessidades e orçamento.

Melhores médicos

30

Turquia

Avaliações

14000+

De pacientes reais

Receba planos de tratamento personalizados gratuitos e escolha a melhor opção. Sem compromisso · Sem pagamentos pelos nossos serviços

Before and after penis enlargement results at Safe Urology Clinic, visible length increase
Before and after penis enlargement results at Safe Urology Clinic, visible length increase
Before and after penile implant surgery results at Safe Urology Clinic, improved function
Before and after penis enlargement results at Safe Urology Clinic with SafeFill procedure
Before and after penis enlargement results at Safe Urology Clinic, visible length increase
Before and after penile implant surgery results at Safe Urology Clinic, improved function
Dr Tuncay Tas

Dr Tuncay Tas

23 anos de experiência
Localização: Turquia, Istambul

Field of Speciality: Urology
Date of Birth: 1980
School of Medicine:  Istanbul University School of Medicine
Graduate Medical Education: University of Health Sciences Taksim Training & Research Hospital
Fellowship: Urological Oncology and Laparoscopic Urology Department of Urology SLK Kliniken Heilbronn University of Heidelberg, Germany
Foreign Language: English

 

Having graduated from Istanbul University, Faculty of Medicine in Istanbul, he pursued Urological Surgery residency at University of Health Sciences Taksim Training & Research Hospital, Istanbul from 2005 to 2010. He subsequently completed fellowship training in Urological Oncology and Laparoscopic Urology at Department of Urology, Heilbronn, Heidelberg University, Germany.Dr. Taş is able to provide patients curative surgery that is extremely precise, preserves sexual function, has minimal blood loss, minimal pain and quick recovery.


Firsts of Safe Urology Clinic in Turkey: Penis injections of:
Cellular derived from adipose tissue
Autologous bone marrow mesenchymal Cellular
Male-Shot

After graduating from Istanbul Medical Faculty in 2004, Dr. Tuncay Taş completed his specialization in Urology at Taksim Training and Research Hospital in 2010. After the training he received in 2006 and 2007 at the “Laparoscopy, Robotics and Oncology Center” of Heildelberg University, Heilbronn SLK Hospital, Germany, he continues to serve his patients in Turkey, especially in the field of Laparoscopic/Robotic Surgery. The majority of Tuncay Taş’s urology practice consists of man sexual health, cancer diagnosis and treatments

His sexual health and wellness practice offers cutting-edge technologies and treatment options for men. Dr Tas offers unique training and clinical protocols for practitioners who want to implement   Penile Implants , Penile Enhancement , SafeFill and MaleShot  into their practice. Dr Taş and his team presented the results of combined P.R.P (MALE-P-SHOT) and SVF application to the penis for the first time in Turkey at the scientific congress and shared the clinical results of these applications. It is also one of the first 5 centers in the world to publish the results of P.R.P (P.SHOT) applications. Dr Taş is one of the urology instructors at ISSCA who is fully involved in regenerative medicine.

(Source: At the congress organized by İHA International Cellular Therapies Association, Dr. Tuncay Taş shared his cell research in clinical regenerative medicine and erectile dysfunction. 2019, Sexual Medicine-Original Research2021, Apr;9(2):100313.doi:10.1016/j.esxm.2020.100313. Epub 2021 30 January.)

Recently Dr. Tas has developed a safe and effective treatment to improve penile circumference and has conducted training with a UK-based certification programme. This novel technique has been shown to have impressive and durable cosmetic results.

OTHER AREAS OF FOCUS

Robotic prostatectomy, Radical prostatectomy, HoLEP, Donor nephrectomy, Nephrectomy, Robotic surgery, Laparoscopic surgery, Prostate cancer, Kidney cancer, Bladder cancer, Testicular cancer, Retroperitoneal lymph node dissection for testicular cancer, Erectile dysfunction, Sexual dysfunction, Male infertility, Varicocelectomy, Male hypogonadism, Penile implant insertion, Urethroplasty, Penile reconstruction, Penile enlargement, Urethral reconstruction, Artificial urinary sphincter implantation, Bladder botox injection, Urodynamic testing, Bladder augmentation, Urinary diversion, Urethral stricture, Ureteral obstruction, HIPEC, Reconstructive surgery, Laparoscopic surgery, Fertility preservation, Minimally invasive surgery, Hypospadias

 

Membership of Scientific Organizations


Turkish Association of Urology
Turkish Medical Association
Association of Endourology
European Association of Urology
International Society for Stem Cells Applications

• Publications
https://scholar.google.com/citations?user=CA59D8UAAAAJ&hl=en

Consulta médicaPreço sob consulta
Liv Hospital Vadistanbul
Dr Murat Ayhan

Dr Murat Ayhan

36 anos de experiência
Clínica certificada
International Organization for Standardization
Joint Commission International
Colorectal Surgery Center for Excellence
+2
Localização: Turquia, Istambul

Areas of Interests

  • Breast cancer
  • Lung cancer
  • Colorectal cancers
  • Gynecological and urogenital cancers
  • Molecular Oncology

Education:

  • Kızıltepe Anatolian High School 2001
  • Dicle University Faculty of Medicine 2007
  • Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
  • Kartal City Hospital 2021
  • Associate Professor of Medical Oncology 2023

Experience:

  • Liv Hospital Ulus
  • Adıyaman University Training and Research Hospital
  • Istanbul Umraniye Training and Research Hospital
  • Istanbul Umraniye Training and Research Hospital

Research:

  • Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
  • Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
  • Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
  • Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
  • Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
  • Publications:
  • Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
  • Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
  • Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
  • Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
  • Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
  • Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
  • Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
  • Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
  • Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
  • Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
  • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
  • Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
  • Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
  • Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
  • Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
  • Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
  • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
  • Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
  • Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
  • Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
  • Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
  • Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
  • Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
  • Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
  • Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
  • Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
  • Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
  • Book Writing:
  • Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
  • Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
  • Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
  • Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

 

Preço do pacote a partir de$3,000
Biruni University Hospital
Didem Karacetin

Didem Karacetin

32 anos de experiência
Clínica certificada
Turkish Medical Association
TEMOS International Healthcare Accreditation
Localização: Turquia, Istambul

Education

  • Faculty of Medicine: Trakya University, 1982-1988
  • Radiation Oncology Residency: Şişli Etfal Training and Research Hospital, 1994-1998
  • Radiation Oncology Residency: Princess Margaret Hospital Toronto, 1996
  • Phytotherapy Master's Degree: Istanbul University Faculty of Pharmacy, 2017-2018

Experience

  • Professor, Head of Department: Health Sciences University Bursa Faculty of Medicine, Department of Radiation Oncology, 2021-2024
  • Professor, Head of Department: Health Sciences University Izmir Faculty of Medicine, Department of Radiation Oncology, 2021-2024
  • Professor: Department of Radiation Oncology, Health Sciences University Istanbul Hamidiye Faculty of Medicine, 2021-2024
  • Lecturer Gelisim University SMYO, 2013-2020

 

Medical Interests

  • Breast Cancer / Intraoperative Radiotherapy
  • Gynaecological Cancers / Brachytherapy Applications
  • Gastrointestinal System Tumours
  • Prostate Cancer / Hydrogel Space Oar Certificate and Application
  • Lung Cancers
  • Brain Tumours
  • Head and Neck Cancers
Preço do pacote a partir de$8,440
Biruni University Hospital
Senem Karabulut

Senem Karabulut

16 anos de experiência
Clínica certificada
Turkish Medical Association
TEMOS International Healthcare Accreditation
Localização: Turquia, Istambul

Education

Istanbul University Cerrahpaşa Faculty of Medicine, 2002
Istanbul Fatih Sultan Mehmet Training and Research Hospital, Internal Medicine, 2010
Istanbul University Oncology Institute (Çapa), Medical Oncology, 2015
Medipol University Faculty of Medicine, Phytotherapy Education, 2018
University of Health Sciences, Vocational School of Health, Molecular Oncology, PhD Program, PhD, 2023

Experience

University Hospital, Newark, New Jersey, USA, Observer (2003-2004)
Siirt State Hospital, Internal Medicine (2010-2011)
Siirt State Hospital, Medical Oncology (2015)
Bakırköy Dr. Sadi Konuk Training and Research Hospital, Medical Oncology (2015-2018)
Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Medical Oncology, (Professor Doctor) (2018-Present)
Forensic Medicine 3. Specialization Board, Medical Oncology, Full Member (2019-Present)
Liv Hospital, Ulus, Park-time, Medical Oncology (2020-2022)
Şişli Kolan International Hospital, Park-time, Medical Oncology (2022-2023)

 

Medical Intrests

  • Gastrointestinal System Tumours (Esophagus - Stomach and Large Bowel Cancer)
  • Hepatobiliary System Tumours (Liver-Biliary Tract and Pancreatic Cancer)
  • Breast Cancer
  • Lung Cancer
  • Genitourinary Cancers
  • Immunotherapies and Target Therapies
  • Molecular Oncology
  • Immunotherapies
  • Target Treatments
  •  

Awards

2010-YDUS (Subspecialty Examination) 14th place in Turkey
2014- Oncology Institute Days Best Poster Award
2015- Turkish Medical Oncology Society Board Exam Qualification
2015- ESMO (European Society for Medical Oncology) Board Exam Qualification

Preço do pacote a partir de$8,440
Biruni University Hospital
Turkan Ozturk Topcu

Turkan Ozturk Topcu

16 anos de experiência
Clínica certificada
Turkish Medical Association
TEMOS International Healthcare Accreditation
Localização: Turquia, Istambul

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

 

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

 

Medical Intrests

  • Breast Cancer
  • Lung Cancer
  • Colon Cancer
  • Stomach Cancer
  • Rectal Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Oesophageal Cancer - Oesophageal Cancer
  • Kidney Cancer
  • Larynx Cancer - Cancer of the Larynx
  • Thyroid Cancer
  • Head and Neck Cancers
  • Gynaecological Cancers
  • Pancreatic Cancer
  • Oesophageal Cancer - Oesophageal Cancer
  • Uterine Cancer
  • Brain Cancers - Brain Tumours
  • Soft Tissue Cancer - Sarcomas
  • Prostate Cancer
  • Bladder Cancer
  • Bile Tract Cancer
  • Testicular Cancer
  • Cervical Cancer
  • Mouth, Tongue, Lip Cancers
  • Gastrointestinal System Cancers
  • Bone Tumours
  • Trachea and Bronchial Cancers
  • Skin Cancers - Skin Cancers
  • Skeletal System Tumours
  • Gallbladder Cancer
  • Mesothelioma
Preço do pacote a partir de$8,440
Biruni University Hospital
Rafet Eren

Rafet Eren

19 anos de experiência
Clínica certificada
Turkish Medical Association
TEMOS International Healthcare Accreditation
Localização: Turquia, Istambul

Education

  • Undergraduate: Istanbul Faculty of Medicine, Istanbul University, 2007
  • MSc (Internal Medicine Department): Marmara University Faculty of Medicine, 2012
  • PhD (Hematology Clinic): Istanbul Training and Research Hospital, 2018
  • Associate Professor (Hematology Clinic): Prof.Dr.Cemil Tascioglu Training and Research Hospital, 2019

Prof. Dr. Rafet Eren graduated from Istanbul Faculty of Medicine in 2007. He completed his Internal Medicine specialty training at Marmara University Faculty of Medicine in 2012. In 2018, he became a Hematology subspecialist at Istanbul Training and Research Hospital. In 2019, he was awarded the title of Associate Professor in the field of Hematology. Afterwards, he worked as a faculty member at Başakşehir Çam and Sakura City Hospital, Bozyaka Training and Research Hospital and Istinye University (Istinye University Bahçeşehir and Liv Hospital Vadistanbul) and is currently working at Biruni University Hospital. Dr. Rafet Eren is a member of Turkish Society of Hematology, Hematology Specialty Society and European Society of Hematology and speaks English fluently. He has around 50 publications in national and international refereed journals.

Scientific Memberships

  • Turkish Hematology Association
  • Hematology Specialty Society
  • Turkish Internal Medicine Specialty Society
  • European Society of Hematology
  •  

Awards 

  • Young Researcher Award (42nd National Hematology Congress), 2016
  • Special Jury Paper Award (3rd Hematologic Oncology Congress), 2015
  • Paper 3rd Prize (2nd Hematologic Oncology and Bone Marrow Transplantation Symposium), 2016
Preço do pacote a partir de$8,440
Liv Hospital Vadistanbul
Emre Merdan Fayda

Emre Merdan Fayda

46 anos de experiência
Clínica certificada
International Organization for Standardization
Joint Commission International
Colorectal Surgery Center for Excellence
+2
Localização: Turquia, Istambul

Areas of Interests

  • MR Linac
  • Three Dimensional Brachytherapy
  • Four Dimensional (4D) Radiotherapy
  • Stereotactic RT & IMRT
  • Breast Cancer, Gynecological Cancers
  • Head – Neck Cancers
  • Urological Tumors, Gastrointestinal Cancers
  • Lung Cancer
  • Central Nervous System Tumors & Metastases
  • Skin Cancers
  • Soft Tissue Tumors

Education:

  • Istinye University Medical Faculty, Professor Doctor (2017 – Continued)
  • Istine University Medical Faculty Associate Professor Doctor (2016 – 2017)
  • Liv Hospital Radiation Medicine Center, Tbilisi, Georgia, Radiation Oncology Consulting Docor (2016 – 2019)
  • Liv Hospital, Radiation Oncology (2015 – Continued)
  • Istanbul University Oncology Institution, Associate Professor (2012 – 2015)
  • Stereotactic Radiotherapy, Thoracic Oncology, University of North Carolina, NC, USA (2010 – 2011)
  • Kocaeli University Radiation Oncology Department, Associate Professor Assistant (2006 – 2009)
  • GATA Radiation Oncology Department, Specialist Doctor, Reserve Officer (2004 – 2005)
  • Istanbul University, Medical Faculty, Dr.R.A. (1999 – 2004)
  • Istanbul University, Medical Faculty, Under-Graduate (1993 – 1999)
     

Experience:

  • Istinye University Medical Faculty
  • Liv Hospital Ulus
  • Istanbul University Oncology Institution
  • University of North Carolina, NC, USA
  • Kocaeli University Medical Faculty
  • Istanbul University, Medical Faculty
Preço do pacote a partir de$3,000
Biruni University Hospital
Ismail Yildiz

Ismail Yildiz

15 anos de experiência
Clínica certificada
Turkish Medical Association
TEMOS International Healthcare Accreditation
Localização: Turquia, Istambul

Education

Eskişehir Osmangazi University Faculty of Medicine, Anesthesiology and Reanimation Residency, 2011, Eskişehir/Turkey
Eskişehir Osmangazi University Faculty of Medicine, Doctor of Medicine Residency, 2000, Eskişehir/Turkey.

 

Experience

Biruni University Hospital, 2021, Istanbul/Turkey
Kilis State Hospital, 2017-2019, Kilis/Turkey
Akdeniz University Faculty of Medicine Hospital (Intensive Care Subspecialty Training), 2014-2017, Antalya/Turkey
Afyon State Hospital, 2013-2014, Afyon/Turkey
Ağrı State Hospital, 2011-2013, Ağrı/Turkey

Scientific Memberships 

Istanbul Medical Chamber
Turkish Intensive Care Association
TARD (Turkish Society of Anesthesiology and Reanimation)
ESICM (European Society of Intensive Care Medicine)
SCCM (Society of Critical Care Medicine)

Anesthesia and Reanimation

  • -ECMO (Extracorporeal Membrane Oxygenation)
  • -Sepsis
  • -Renal Replacement Therapy
  • -Echocardiography, Ultrasonography
  • -Brain Death, Organ Donation
  • -ARDS (Acute Respiratory Distress Syndrome)
  • -Organ Transplant
Preço do pacote a partir de$8,440
Biruni University Hospital
Didem Tastekin

Didem Tastekin

22 anos de experiência
Clínica certificada
Turkish Medical Association
TEMOS International Healthcare Accreditation
Localização: Turquia, Istambul

Education

  • Doctor of Medicine: Necmettin Erbakan University Meram Faculty of Medicine, 1994
  • Internal Medicine Residency: Atatürk University Faculty of Medicine, 2004
  • Internal Medicine Residency: Kafkas University Faculty of Medicine, 2007
  • Medical Oncology Subspecialty Residency: Selçuk University Faculty of Medicine, 2010
  • Medical Oncology Subspecialty Training: Istanbul University Oncology Institute, 2013

 

Experience

  • Dailiye Assistant: Atatürk University Faculty of Medicine, 2005
  • Asst. Assoc. Prof. Dr.: Kafkas University, 2006-2007
  • Assistant Prof.: Selcuk University - Medical Oncology, 2007-2010
  • Assistant Prof.: Istanbul University Oncology Institute - Medical Oncology, 2012-2013
  • Uzm. Dr.: Istanbul University Oncology Institute - Medical Oncology, 2013-2017
  • Assoc. Prof. Dr.: Istanbul University Oncology Institute - Medical Oncology, 2017-2023
  • Prof. Dr.: Istanbul University Oncology Institute - Medical Oncology, 2023-present

 

Scientific Memberships

  •  
  • Turkish Society of Medical Oncology
  • European Society of Medical Oncology (ESMO)
  • American Society of Clinical Oncology (ASCO)
  • Turkish Internal Medicine Specialty Society

 

Awards

  • 2018: "Best Researcher of the Year" award, Istanbul University Oncology Institute
  • 2016: TUBITAK Incentive Award in the field of "Cancer Research"
Preço do pacote a partir de$8,440
Menfis Health Novimaj
Isil Yurdaisik

Isil Yurdaisik

36 anos de experiência
Clínica certificada
Turkish Medical Association
Localização: Turquia, Istambul

O médico conduziu uma pesquisa significativa sobre a dose efetiva cumulativa de radiação de tomografias computadorizadas de tórax em pacientes com COVID-19. Este trabalho destaca a importância de aderir às diretrizes para minimizar a exposição desnecessária, refletindo um compromisso com a segurança do paciente e a prática baseada em evidências.<\/p>

Consulta médicaPreço sob consulta

Você viu 10 de 30 médicos

Escolher clínica no exterior pode ser estressante. No Bookimed, com mais de 800K pacientes atendidos, entendemos preocupações. Sabemos encontrar médicos confiáveis, melhores opções de custo-benefício e soluções até para casos complexos. Estamos aqui para orientar em cada etapa.

Yan Matsiivskiy

Chefe da Equipe de Coordenadores Médicos

4300++ jornadas de pacientes acompanhadas

3 anos na Bookimed

278 pacientes de Turkey encontraram seu médico conosco este mês

Como você encontrará seu médico ideal

1

Quiz de 2 minutos

Conte-nos seu objetivo, orçamento e prazo

2

Combinação Humana + IA

Nosso algoritmo encontra correspondências, o coordenador verifica a adequação

3

Suas opções prontas

Compare preços, pacotes, datas. Converse com seu coordenador

Muitas opções?

Seu pessoal O coordenador da Bookimed ajuda você a encontrar o cirurgião ideal para suas necessidades

  • Apoio 24/7 em todas as etapas
  • Ajuda a encontrar o médico ideal e gerencia toda a comunicação com as clínicas
  • Coordena sua viagem, acomodação e transferências

Orientando seu tratamento

Coordenadores pessoais com formação médica

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk